Select Language
HLA-A*1101 & B2M & KRAS (VVVGAGGVGK)
HLA-A*1101 & B2M & KRAS (VVVGAGGVGK) Product List
- Product Category
Protein (4)
- Product Status
Launched (4)
- Species
Human (4)
- Tag
His Tag & Avi Tag (2)His Tag (2)
- Conjugate
Biotin-labeled (1)AF647 Labeled (1)Unconjugated (1)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT HLS-H52E7 |  Human | HEK293 | Unconjugated Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Complex Protein (Monomer, MALS verified) |  |  | |
HOT HLS-H82E6 | Human | HEK293 | Biotinylated Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Complex Protein (Monomer, MALS verified) | | | |
HLS-HA2H8 | Human | HEK293 | Alexa Fluor™ 647-Labeled Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Complex Protein (Monomer) | | | |
HLS-HP2H6 | Human | HEK293 | PE-Labeled Human HLA-A*11:01&B2M&KRAS (VVVGAGGVGK) Tetramer Protein | |
Total: 4
- 1
HLA-A*1101 & B2M & KRAS (VVVGAGGVGK) Background
The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*1101 KRAS (VVVGAGGVGK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M, and VVVGAGGVGK peptide of the KRAS.
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tavilermide | MIM-D3; NMG938VJ6T (UNII code) | Phase 3 Clinical | Mimetogen Pharmaceuticals | Keratoconjunctivitis Sicca; Dry Eye Syndromes | Details |
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
| VC-004 | VC004; VC-004; VC 004 | Phase 3 Clinical | Solid tumours; Cancer Pain; Pruritus; Dermatitis | Details | |
| SNA-125 | CT-340; SNA-125 | Phase 2 Clinical | Sienna Biopharmaceuticals Inc, Creabilis Sa | Pruritus; Psoriasis; Dermatitis, Atopic | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Milciclib maleate | PHA-848125; TZLS-201; PHA-848125C; PHA-125; PHA-848125AC | Phase 2 Clinical | Tiziana Life Sciences Plc, Nerviano Medical Sciences Srl | Solid tumours; Thymoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| XZP-5955 | XZP-5955 | Phase 2 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| BEN-2293 | BEN-00002293; BEN-2293 | Phase 2 Clinical | Benevolentai Bio Ltd | Dermatitis, Atopic | Details |
| TQB-3558 | TQB-3558; CT-3417 | Phase 1 Clinical | Solid tumours | Details | |
| BPI-28592 | BPI-28592 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
| ACD-856 | ACD-856 | Phase 1 Clinical | Alzecure Pharma Ab | Alzheimer Disease; Cognition Disorders | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| AK-1830 | AK-1830 | Phase 1 Clinical | Array Biopharma | Inflammation | Details |
| BR-01T | BR01T; BR-01T | Phase 1 Clinical | Xiyuan Anjian Pharmaceutical (Shanghai) Co Ltd | Low Back Pain | Details |
| ND-003 (NewDEL Biotech) | ND-003; ND003 | Phase 1 Clinical | Shenzhen NewDEL Biotech Co Ltd | Solid tumours; Neoplasms; Idiopathic Pulmonary Fibrosis; Renal fibrosis; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Dermatitis, Atopic | Details |
| JND-5932 | JND-5932; JND5932 | Phase 1 Clinical | Jinan University | Neoplasms | Details |
| PBI-200 | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms | Details |
| FCN-098 | FCN-098; FCN098 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| E-2511 | E2511; E-2511 | Phase 1 Clinical | Eisai Inc | Details | |
| Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
| Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details | |
| VMD-928 | VMD-928 | Phase 1 Clinical | Vm Oncology Llc | Head and Neck Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Mesothelioma; Carcinoma, Adenoid Cystic; Sarcoma; Breast Neoplasms; Thymoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Lymphoproliferative Disorders; Colorectal Neoplasms; Sarcoma; Brain Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare | 2018-11-26 | Glioma; Multiple Myeloma; Urinary Bladder Neoplasms; Histiocytosis, Langerhans-Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Lung Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Fibrosarcoma; Rhabdomyosarcoma; Medulloblastoma; Leukemia; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Colonic Neoplasms | Details |
| Repotrectinib | TPX-0005; BMS-986472; ZL-2308 | Approved | Augtyro, 奥凯乐 | United States | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb Company | 2023-11-15 | Solid tumours; Neoplasms; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland